Compare Stocks

Date Range: 

 Taysha Gene TherapiesTCR2 TherapeuticsBlack Diamond TherapeuticsPassage BioAdverum Biotechnologies
SymbolNASDAQ:TSHANASDAQ:TCRRNASDAQ:BDTXNASDAQ:PASGNASDAQ:ADVM
Price Information
Current Price$21.20$20.50$25.50$17.29$3.78
52 Week RangeBuyBuyBuyBuyHold
MarketRank™
Overall Score1.81.61.61.81.6
Analysis Score3.53.53.53.44.2
Community Score4.02.62.73.32.3
Dividend Score0.00.00.00.00.0
Ownership Score0.81.71.71.71.7
Earnings & Valuation Score0.60.00.00.60.0
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyHold
Consensus Price Target$43.92$43.29$51.50$27.32$14.88
% Upside from Price Target107.15% upside111.15% upside101.96% upside57.98% upside293.52% upside
Trade Information
Market Cap$801.72 million$781.81 million$921.52 million$933.26 million$370.16 million
BetaN/A2.13N/AN/A1.72
Average Volume85,966513,130413,359412,3151,735,425
Sales & Book Value
Annual RevenueN/AN/AN/AN/A$250,000.00
Price / SalesN/AN/AN/AN/A1,480.66
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book ValueN/A$6.68 per share($1.44) per shareN/A$2.71 per share
Price / BookN/AN/AN/AN/A1.39
Profitability
Net IncomeN/A$-47,600,000.00$-35,260,000.00N/A$-64,490,000.00
EPSN/A($4.62)($16.99)N/A($1.01)
Trailing P/E Ratio0.00N/AN/A0.00N/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/AN/AN/A
Return on Equity (ROE)N/A-35.51%-22.28%N/A-32.23%
Return on Assets (ROA)N/A-34.02%-17.91%N/A-28.02%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/AN/AN/A
Current Ratio24.02%32.38%29.67%18.30%28.53%
Quick Ratio24.02%32.38%29.66%18.30%28.53%
Ownership Information
Institutional Ownership Percentage42.19%82.05%65.78%67.59%97.41%
Insider Ownership PercentageN/A27.99%N/AN/A12.40%
Miscellaneous
Employees381186974167
Shares Outstanding37.82 million38.14 million36.14 million53.98 million97.93 million
Next Earnings Date5/11/2021 (Confirmed)5/13/2021 (Estimated)8/10/2021 (Estimated)8/12/2021 (Estimated)8/9/2021 (Estimated)
OptionableNot OptionableNot OptionableNot OptionableNot OptionableOptionable
SourceHeadline
Adverum Biotechnologies (NASDAQ:ADVM) Posts Quarterly  Earnings Results, Beats Estimates By $0.09 EPSAdverum Biotechnologies (NASDAQ:ADVM) Posts Quarterly Earnings Results, Beats Estimates By $0.09 EPS
americanbankingnews.com - May 7 at 5:04 PM
Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Currently 606.28% Below Its 52-week High But The Upside Potential May Surprise YouAdverum Biotechnologies, Inc. (NASDAQ:ADVM) Currently 606.28% Below Its 52-week High But The Upside Potential May Surprise You
marketingsentinel.com - May 7 at 1:09 PM
Adverum Biotechnologies (ADVM) Reports Q1 Loss, Tops Revenue EstimatesAdverum Biotechnologies (ADVM) Reports Q1 Loss, Tops Revenue Estimates
finance.yahoo.com - May 6 at 10:03 PM
Adverum Biotechnologies: Q1 Earnings SnapshotAdverum Biotechnologies: Q1 Earnings Snapshot
miamiherald.com - May 6 at 5:02 PM
Adverum Biotechnologies Inc. [ADVM] moved up 1.39: Why It’s ImportantAdverum Biotechnologies Inc. [ADVM] moved up 1.39: Why It’s Important
dbtnews.com - May 6 at 5:02 PM
Adverum Reports First Quarter 2021 ResultsAdverum Reports First Quarter 2021 Results
finance.yahoo.com - May 6 at 5:02 PM
Glass Lewis Joins ISS In Recommending Adverum Shareholders Vote for All Three Independent Sonic Director NomineesGlass Lewis Joins ISS In Recommending Adverum Shareholders Vote for All Three Independent Sonic Director Nominees
finance.yahoo.com - May 6 at 12:02 PM
ISS Recommends Adverum Stockholders Vote to Elect Sonics Three Independent, Highly Qualified NomineesISS Recommends Adverum Stockholders Vote to Elect Sonics Three Independent, Highly Qualified Nominees
financialbuzz.com - May 5 at 9:41 PM
Adverum Biotechnologies (ADVM) "Neutral" Rating Reiterated at Chardan CapitalAdverum Biotechnologies' (ADVM) "Neutral" Rating Reiterated at Chardan Capital
americanbankingnews.com - May 5 at 3:27 PM
Adverum Biotechnologies (NASDAQ:ADVM) Given Hold Rating at Truist SecuritiesAdverum Biotechnologies (NASDAQ:ADVM) Given Hold Rating at Truist Securities
americanbankingnews.com - May 5 at 1:56 PM
Adverum Biotechnologies (ADVM) "Sector Perform" Rating Reaffirmed at Royal Bank of CanadaAdverum Biotechnologies' (ADVM) "Sector Perform" Rating Reaffirmed at Royal Bank of Canada
americanbankingnews.com - May 5 at 12:56 PM
Adverum Biotechnologies (NASDAQ:ADVM) PT Lowered to $11.00 at SVB LeerinkAdverum Biotechnologies (NASDAQ:ADVM) PT Lowered to $11.00 at SVB Leerink
americanbankingnews.com - May 5 at 10:14 AM
Adverum Biotechnologies: One Adverse Event Too ManyAdverum Biotechnologies: One Adverse Event Too Many
seekingalpha.com - May 4 at 7:00 PM
Adverum BiotechnologiesInc. (NASDAQ:ADVM) – An Analysis Is What You NeedAdverum BiotechnologiesInc. (NASDAQ:ADVM) – An Analysis Is What You Need
stocksregister.com - May 4 at 1:55 PM
ISS Recommends Adverum Stockholders Vote to Elect Sonic’s Three Independent, Highly Qualified NomineesISS Recommends Adverum Stockholders Vote to Elect Sonic’s Three Independent, Highly Qualified Nominees
finance.yahoo.com - May 4 at 8:51 AM
Will current price volatility hamper Adverum Biotechnologies Inc. (ADVM) future potential?Will current price volatility hamper Adverum Biotechnologies Inc. (ADVM) future potential?
marketingsentinel.com - May 3 at 1:07 PM
Adverums Wet AMD Gene Therapy Shows Long Term Benefit In Treatment-Experienced PatientsAdverum's Wet AMD Gene Therapy Shows Long Term Benefit In Treatment-Experienced Patients
finance.yahoo.com - May 3 at 1:07 PM
SVB Leerink Lowers Adverum Biotechnologies (NASDAQ:ADVM) to Market PerformSVB Leerink Lowers Adverum Biotechnologies (NASDAQ:ADVM) to Market Perform
americanbankingnews.com - May 3 at 8:18 AM
FY2022 EPS Estimates for Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Lifted by Truist SecuritiFY2022 EPS Estimates for Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Lifted by Truist Securiti
americanbankingnews.com - May 3 at 4:50 AM
Adverum Biotechnologies (NASDAQ:ADVM) Downgraded by Lifesci Capital to "Market Perform"Adverum Biotechnologies (NASDAQ:ADVM) Downgraded by Lifesci Capital to "Market Perform"
americanbankingnews.com - May 1 at 8:44 AM
Adverum Biotechnologies Inc. [ADVM] stock Downgrade by Truist analyst, price target now $9Adverum Biotechnologies Inc. [ADVM] stock Downgrade by Truist analyst, price target now $9
dbtnews.com - April 30 at 10:18 PM
Traders Buy High Volume of Call Options on Adverum Biotechnologies (NASDAQ:ADVM)Traders Buy High Volume of Call Options on Adverum Biotechnologies (NASDAQ:ADVM)
americanbankingnews.com - April 29 at 8:00 PM
BRIEF-The Sonic Fund Ii, L.P. Comments On Adverum Update Regarding Infinity Phase 2 Trial Of Advm-022BRIEF-The Sonic Fund Ii, L.P. Comments On Adverum Update Regarding Infinity Phase 2 Trial Of Advm-022
msn.com - April 29 at 4:15 PM
Adverum Bio’s shares plummet after patient in gene therapy study loses visionAdverum Bio’s shares plummet after patient in gene therapy study loses vision
medcitynews.com - April 29 at 4:15 PM
Adverum Confirms Patient Loses Sight in Eye Treated with Its Gene TherapyAdverum Confirms Patient Loses Sight in Eye Treated with Its Gene Therapy
genengnews.com - April 29 at 4:15 PM
DateCompanyBrokerageAction
4/26/2021Taysha Gene TherapiesChardan CapitalReiterated Rating
4/19/2021Taysha Gene TherapiesMorgan StanleyBoost Price Target
3/1/2021Taysha Gene TherapiesWilliam BlairInitiated Coverage
1/4/2021Taysha Gene TherapiesOppenheimerInitiated Coverage
10/19/2020Taysha Gene TherapiesJefferies Financial GroupInitiated Coverage
10/19/2020Taysha Gene TherapiesThe Goldman Sachs GroupInitiated Coverage
4/11/2021TCR2 TherapeuticsMizuhoReiterated Rating
3/17/2021TCR2 TherapeuticsSVB LeerinkLower Price Target
3/11/2021TCR2 TherapeuticsBMO Capital MarketsLower Price Target
3/11/2021TCR2 TherapeuticsPiper SandlerBoost Price Target
12/14/2020TCR2 TherapeuticsHC WainwrightBoost Price Target
11/30/2020TCR2 TherapeuticsRoth CapitalBoost Price Target
8/12/2020TCR2 TherapeuticsTruist FinancialInitiated Coverage
7/27/2020TCR2 TherapeuticsWedbushBoost Price Target
1/19/2021Black Diamond TherapeuticsCanaccord GenuityReiterated Rating
11/24/2020Black Diamond TherapeuticsBerenberg BankInitiated Coverage
2/24/2020Black Diamond TherapeuticsCowenInitiated Coverage
2/24/2020Black Diamond TherapeuticsJPMorgan Chase & Co.Initiated Coverage
2/4/2021Passage BioGuggenheimInitiated Coverage
12/11/2020Passage BioSmith Barney CitigroupInitiated Coverage
12/11/2020Passage BioCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellInitiated Coverage
5/5/2021Adverum BiotechnologiesRoyal Bank of CanadaReiterated Rating
5/5/2021Adverum BiotechnologiesTruist SecuritiesReiterated Rating
4/29/2021Adverum BiotechnologiesLifesci CapitalDowngrade
3/2/2021Adverum BiotechnologiesCantor FitzgeraldReiterated Rating
12/15/2020Adverum BiotechnologiesUBS GroupInitiated Coverage
11/12/2020Adverum BiotechnologiesRaymond JamesUpgrade
(Data available from 5/8/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected]arketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.